The problem of chronic viral hepatitis C is among the most actual global health problems. The article is devoted to organization of medical care and drug provision for patients with chronic hepatitis C in Moscow. Considering high relevance of chronic viral hepatitis C for city healthcare, Moscow Department of Health initiated drug provision program for citizens with chronic viral hepatitis C. Practical implementation of the program began in 2016 as a part of the Moscow State Program «Development of Moscow Health Care in 2012—2020». The aim of the work was to analyze the results of implementation of drug provision program for patients with chronic hepatitis C in Moscow. Material and methods. The work was carried out by the specialists of the Center for the Treatment of Chronic Viral Hepatitis that is a structural unit of the Infectious Clinical Hospital №1. Current antiviral combinations and modes of therapy were administered: genotype 1 — Viekira Pak (n=642), Viekira Pak + ribavirin (n=259), daclatasvir + asunaprevir (n=745) and triple therapy PEG — IFN + ribavirin + simeprevir (n=896); genotypes 2 and 3 — standard combination of PEG-IFN + ribavirin. Overall number of patients provided with antiviral medicines in 2016—2018 was 6735. Results. The effectiveness of treatment (persistent response in 12 weeks after the end of the course) ranged from 88.6 to 97%. These results correspond to those of the world’s leading clinics and are accompanied by decrease of the incidence of chronic viral hepatitis C in Moscow.